A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)

LESSONS LEARNED. Dual epidermal growth factor receptor (EGFR)‐directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy. A significantly longer o...

Descripción completa

Detalles Bibliográficos
Autores principales: Halfdanarson, Thorvardur R., Foster, Nathan R., Kim, George P., Meyers, Jeffrey P., Smyrk, Thomas C., McCullough, Ann E., Ames, Matthew M., Jaffe, Jeffrry P., Alberts, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516109/
https://www.ncbi.nlm.nih.gov/pubmed/30679315
http://dx.doi.org/10.1634/theoncologist.2018-0878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516109/
https://www.ncbi.nlm.nih.gov/pubmed/30679315
http://dx.doi.org/10.1634/theoncologist.2018-0878

Ejemplares similares